Y-mAbs Therapeutics (YMAB) to Release Quarterly Earnings on Tuesday

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) is expected to release its earnings data before the market opens on Tuesday, March 4th. Analysts expect Y-mAbs Therapeutics to post earnings of ($0.13) per share and revenue of $26.70 million for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

Y-mAbs Therapeutics Stock Performance

NASDAQ YMAB traded up $0.14 during trading on Friday, hitting $5.56. The stock had a trading volume of 727,846 shares, compared to its average volume of 470,124. Y-mAbs Therapeutics has a 12 month low of $5.28 and a 12 month high of $20.90. The company's 50-day moving average price is $6.64 and its two-hundred day moving average price is $10.76. The company has a market capitalization of $248.85 million, a PE ratio of -10.29 and a beta of 0.67.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Wedbush reissued an "outperform" rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Friday, January 10th. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a "buy" rating and a $17.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Finally, Oppenheimer began coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They set an "outperform" rating and a $23.00 target price on the stock. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $20.89.

Remove Ads

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.